Anti-adenovirus activity of epiandrosterone and dehydroepiandrosterone derivatives

Chemotherapy

Volumn 56, Issue 2, 2010, Pages 158-165

  Romanutti, Carina ^a   Bruttomesso, Andrea C ^a   Castilla, Viviana ^a   Galagovsky, Lydia R ^a   Wachsman, Mónica B ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Adenovirus; Anti adenovirus activity; Antiviral activity; Dehydroepiandrosterone analogues; DHEA

Indexed keywords

16ALPHA HYDROXYPRASTERONE; 17 OXO 5ALPHA ANDROSTAN 3BETA YL ACETATE; 17 OXO 5ALPHA ANDROSTAN 3BETA,16ALPHA DIYL DIACETATE; 17 OXO 5ALPHA ANDROSTAN 3BETA,16BETA DIYL DIACETATE; 17 OXOANDROST 5 EN 3BETA YL ACETATE; 17 OXOANDROST 5 EN 3BETA,16ALPHA DIYL DIACETATE; 17,17 ETHYLENDIOXY 5ALPHA ANDROST 15 EN 3BETA OL; 17,17 ETHYLENDIOXY 5ALPHA ANDROSTAN 16ALPHA BROMO 3BETA OL; 17,17 ETHYLENDIOXY 5ALPHA ANDROSTAN 3BETA OL; 17,17 ETHYLENDIOXY 5ALPHA ANDROSTAN 3BETA YL ACETATE; 17,17 ETHYLENDIOXYANDROST 5 EN 3BETA OL; 21 NORPREGNA 5,17(20) DIEN 3BETA,16ALPHA DIYL DIACETATE; 3BETA HYDROXY 5ALPHA ANDROST 15 EN 17 ONE; 3BETA,15ALPHA DIHYDROXY 5ALPHA ANDROSTAN 17 ONE; 3BETA,15BETA DIHYDROXY 5ALPHA ANDROSTAN 17 ONE; 3BETA,16ALPHA DIHYDROXY 5ALPHA ANDROSTAN 17 ONE; 3BETA,6ALPHA DIHYDROXY 5ALPHA ANDROSTAN 17 ONE; ANDROSTA 5,16 DIEN 3BETA,17 DIYL DIACETATE; ANTIVIRUS AGENT; CIDOFOVIR; EPIANDROSTERONE; PRASTERONE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADENOVIRUS; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN SYNTHESIS REGULATION; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS REPLICATION; WESTERN BLOTTING;

ADENOVIRIDAE; ANDROSTERONE; ANIMALS; ANTIVIRAL AGENTS; BLOTTING, WESTERN; CERCOPITHECUS AETHIOPS; CYTOSINE; DEHYDROEPIANDROSTERONE; HUMANS; MICE; PHOSPHONIC ACIDS; VERO CELLS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 77950950691     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313530     Document Type: Article

References (42)

1. Mei YF, Wadell G: Molecular determinants of adenovirus tropism. Curr Top Microbiol Immunol 1995; 199: 213-228.
2. Kojaoghlanian T, Flomenberg P, Horwitz MS: The impact of adenovirus infection on the immunocompromised host. Rev Med Virol 2003; 13: 155-171.
3. Kinchington PR, Romanowski EG, Gordon YJ: Prospects for adenovirus antivirals. J Antimicrob Chemother 2005; 55: 424-429.
4. Esimone CO, Grunwald T, Nworu CS, Kuate S, Proksch P, Überla K: Broad spectrum antiviral fractions from the lichen Ramalina farinacea (L.) Ach. Chemotherapy 2009; 55: 119-126.
5. Hoffman JA, Shah AJ, Ross LA, Kapoor N: Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 388-394.
6. Kaneko H, Kato K, Mori S, Shigeta S: Antiviral activity of NMSO3 against adenovirus in vitro. Antiviral Res 2001; 52: 281-288.
7. Bordigoni P, Carret AS, Venard V, Witz F, Le Fou A: Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2001; 32: 1290-1297. (Pubitemid 32405900)
8. La Rosa AM, Champlin RE, Mitza M, Gajewski J, Giralt S, Roiston KV, Raad I, Jacobson K, Kontoyiannis D, Elting L, Whimbey E: Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis 2001; 32: 871-876. (Pubitemid 32524820)
9. Legrand F, Berrobi D, Honbou N, Freymuth F, Faye A, Davel M, Mongenot JF, Peuchmaur M, Vilmer E: Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Bone Marrow Transplant 2001; 27: 621-626.
10. Gavin PJ, Katz RZ: Intravenous ribavirin treatment for severe adenovirus diseases in immunocompromised children. Pedriatrics 2002; 110: 1-8.
11. Lankester A, Heemkerk CB, Claas EC, Schilham MW, Beersma MF, Bredius RG, van Tol MJ, Kroes AC: Effect of ribavirin on the plasma viral DNA load in patients with disseminating adenovirus infection. Clin Infect Dis 2004; 38: 1521-1525.
12. Robel P, Bourreau E, Corpechot C, Dang DC, Halberg F, Clarke CJ: Dehydroepiandrosterone: a potential signalling molecule for neocortical organization during development. Steroid Biochem 1987; 27: 649-655.
13. Dalla Valle L, Couet J, Labrie Y, Simard J, Belvedere P, Simontacchi C: Occurrence of cytochrome P450c17 mRNA and dehydroepiandrosterone biosynthesis in the rat gastrointestinal tract. Mol Cell Endocrinol 1995; 111: 83-92.
14. Loria RM, Inge TH, Cook SS, Szakal AK, Regelson W: Protection against acute lethal viral infections with the native steroid dehydroepiandrosterone (DHEA). J Med Virol 1988; 26: 301-314.
15. Van Vollenhoven R: Dehydroepiandrosterone for the treatment of systemic lupus erythematosus. Expert Opinion Pharmacother 2002; 3: 23-31.
16. Pedersen NC, North TW, Rigg R, Reading C, Higgins J, Leutenegger C, Henderson GL: Bromo-epiandrosterone therapy modulates experimental feline immunodeficiency virus viremia: initial enhancement leading to long-term suppression. Vet Immunol Immunopathol 2003; 94: 133-148.
17. Mortola J, Yen SJ: The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinal Metab 1990; 71: 696-704.
18. Lardy H, Kneer N, Wei Y, Partridge B, Marwah P: Ergosteroids II: biologically active metabolites and synthetic derivatives of dehydroepiandrosterone. Steroids 1998; 63: 158-165.
19. Henderson E, Yang J, Schwartz A: Dehydroepiandrosterone (DHEA) and synthetic DHEA analogs are modest inhibitors of HIV-1 IIIB replication. AIDS Res Hum Retroviruses 1992; 8: 625-631.
20. Bradley W, Kraus L, Good R, Day N: Dehydroepiandrosterone inhibits replication of feline immunodeficiency virus in chronically infected cells. Vet Immunol Immunopathol 1995; 46: 159-168.
21. Diallo K, Loemba H, Oliveira M, Mavoungou DD, Wainberg MA: Inhibition of human immunodeficiency virus type-1 (HIV-1) replication by immunor (IM28), a new analog of dehydroepiandrosterone. Nucleosides Nucleotides Nucleic Acids 2000; 19: 2019-2024.
22. Mavoungou D, Poaty-Mavoungou V, Akoume M, Ongali B, Mavoungou E: Inhibition of human immunodeficiency virus type-1 (HIV-1) glycoprotein-mediated cell-cell fusion by immunor (IM28). Virol J 2005; 11: 9-10.
23. Acosta EG, Bruttomesso AC, Bisceglia JA, Wachsman MB, Galagovsky LR, Castilla V: Dehydroepiandrosterone, epiandrosterone and synthetic derivatives inhibit Junin virus replication in vitro. Virus Res 2008; 135: 203-212.
24. Romanutti C, Bruttomesso AC, Bisceglia JA, Castilla V, Galagovsky LR, Wachsman MB: In vitro antiviral activity of dehydroepiandrosterone and synthetic derivatives against vesicular stomatitis virus. Vet J 2009; 182: 327-335.
25. Heftmann E: Androgens; in Steroid Biochemistry. London, Academic Press, 1970, pp 115-130.
26. Sondheimer F, Burstein S, Mechoulam R: Syntheses in the cardiac aglycone field. III. The conversion of a 14- - to a 14--hydroxy group in the androstane series. The ultraviolet spectra of- 15-androsten-17-ones. J Am Chem Soc 1960; 82: 3209-3212.
27. Defaye G, Chambaz EM: Synthesis of 15- - hydroxylated derivatives of dehydroisoandrosterone and isoandrosterone. Tetrahedron Lett 1978; 19: 3849-3850.
28. Numazawa M, Nagaoka M: Stereospecific synthesis of 16--hydroxy-17-oxo steroids by controlled alkaline hydrolysis of corresponding 16-bromo-17-ketones and its reaction mechanism. J Org Chem 1982; 47: 4024-4029.
29. Numazawa M, Osawa Y: Improved synthesis of 16 alpha-hydroxylated androgens: intermediates of estriol formation in pregnancy. Steroids 1978; 32: 519-527.
30. Johnson WS, Gastambide B, Pappo R: The action of lead tetra-acetate on an enol acetate. Their interconversion and rearrangement. J Am Chem Soc 1957; 79: 1991-1994.
31. Iwasaki M: The Reformatsky reaction of 17-ketosteroids with ethyl--bromopropionate. Steroids 1967; 9: 373-386.
32. Leeds NS, Fukushima DK, Gallager TF: Studies of steroid ring D epoxides of enol acetates: a new synthesis of estriol and of androstane-3- ,16- ,17--triol. J Am Chem Soc 1954; 76: 2943-2948.
33. Bruttomesso AC, Gros EG, Ponce MA, Balsells RE: Photooxygenation of pregnanes. Helv Chim Acta 2004; 87: 2987-3003.
34. Denizot F, Lang R: Rapid colorimetric assay for cell growth and survival. J Immunol Methods 1986; 89: 271-277.
35. Wachsman MB, López EMF, Ramírez JA, Galagovsky LR, Coto CE: Antiviral effect of brassinosteroids against herpes virus and arenaviruses. Antivir Chem Chemother 2000; 11: 71-77.
36. Talarico LB, Castilla V, Rámirez, JA, Galagovsky LR, Wachsman MB: Synergistic in vitro interactions between (22S,23S)-3--bromo-5- ,22,23-trihydroxystigmastan-6-one and foscarnet against herpes simples virus type 1. Chemotherapy 2006; 52: 38-42.
37. Loria RM, Padgett DA: Androstenediol regulates systemic resistance against lethal infections in mice. Arch Virol 1992; 127: 103-115.
38. Padgett DA, Loria RM, Sheridan JF: Steroid hormone regulation of antiviral immunity. J Neuroimmunol 1997; 78: 203-311.
39. Chang CC, Ou YC, Rang SL, Chen CJ: Antiviral effect of dehydroepiandrosterone on Japanese encephalitis virus infection. J Gen Virol 2005; 86: 2513-2523.
40. Ashida K, Goto K, Zhao Y, Okabe T, Yanase T, Takayanagi R, Nomura M, Nawata H: Dehydroepiandrosterone negatively regulates the p38 mitogen-activated protein kinase pathway by a novel mitogen-activated protein kinase phosphatase. Biochim Biophys Acta 2005; 1728: 84-94.
41. Ziegler CG, Sicard F, Sperber S, Ehrhart-Bornstein M, Bornstein SR, Krug AW: DHEA reduces NGF-mediated cell survival in serum-deprived PC12 cells. Ann NY Acad Sci 2006; 1073: 306-311.
42. Schümann M, Dobbelstein M: Adenovirusinduced extracellular signal-regulated kinase phosphorylation during the late phase of infection enhances viral protein levels and virus progeny. Cancer Res 2006; 66: 1282-1288.